Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease:

Background:Clinicians often utilize off-label dose escalation of ustekinumab (UST) in Crohn’s disease (CD) patients with disease refractory to standard dosing. Previous studies report mixed results...